A. Consoli

TL;DR: In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, orNonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semag lutide.

TL;DR: This article will attempt to formulate an answer to whether or not thiazolidinediones (namely pioglitazone) should still be used in the treatment of type 2 diabetes mellitus by critically reviewing the available data on the numerous advantages and the potentially worrying shortcomings of piog litazone treatment in T2DM.

TL;DR: This review evaluates the currently available hypoglycemic drugs and the current indications to the Italian diabetology community, specifically with regard to the treatment of adults aged 75 years or older with diabetes, including the unmet needs by the guidelines.

TL;DR: The main safety concern about GLP-1Rx agonists use is the possible association with increased risk of pancreatitis and/or tumors, which stems mainly from limited observations in animal models not confirmed in similar studies.

TL;DR: In un’epoca di cambiamenti continui delle conoscenze scientifiche e delle relative applicazioni cliniche, appare cruciale un aggiornamento sistematico a partire dalla revisione puntuale della letteratura scientifica disponibile.